NATURAL HEALTH TRENDS CORP (NHTC)

Wholesale-Miscellaneous Nondurable Goods · market cap $9M · as of 2026-07-19

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-04 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Natural Health Trends Corp (NHTC) is a micro-cap wholesale consumer goods company with 133 employees and a $16M market cap, primarily generating ~$40M in annual revenue from its core direct-sales business. Anomalously, the company also carries a Phase 2 clinical asset — Heptex — being evaluated for nonalcoholic steatohepatitis (NASH), a pipeline that appears entirely disconnected from its wholesale consumer goods operating core.

The catalyst path

2026-11-04 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Heptex	Phase 2	Nonalcoholic Steatohepatitis

Price & technical context

3-month

-52.8%

6-month

-71.0%

12-month

-81.1%

52-wk range

$0.85–$4.51

vs 50-day MA

-36.6%

vs 200-day MA

-64.6%

Realized vol

81.8%

Max drawdown

-87.2%

Daily closes through 2026-10-21. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for NHTC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.